Introduction {#sec1-1}
============

Hematological malignancies (HM) are a group of diseases characterized by a spectrum of genetic markers which have diagnostic and prognostic implications. Conventional cytogenetic study (CCS) has been the gold standard for more than five decades for detecting genetic alterations that are greater than 10 MB in size (Peterson et al., 2015). CCS has paved the way in identifying specific chromosomal aberrations associated with clinically and morphologically definitive subsets of HMs. In the recent past, fluorescence in situ hybridization (FISH) has become a reliable and rapid complementary test in targeting critical genetic events associated with diagnostics and prognosis in HMs. Although CCS is advantageous in providing a global purview of the chromosome complement, there are many disadvantages. The technique relies upon dividing cells causing high failure rates due to low mitotic index. Even when metaphases are available for analysis, poor morphology of chromosomes hinder identification of aberrations. These factors directly influence its ability in establishing minor clone population during analysis. FISH has addressed these issues by targeting interphase cells in addition to metaphases (Sreekantaiah, 2007). Although complementary FISH testing increases the overall detection of aberrations, its benefit is not uniform across all types of HMs. Recent comparative studies in Myelodysplastic Syndrome (MDS) have showed that FISH does not add value to CCS findings (He et al., 2016) while a similar study contradicted that both modalities are equally important in prognostication of MDS (Kokate et al., 2017). On the other hand, FISH analysis in lymphoid malignancies have resulted in the expansion and identification of distinct subsets of the disease (Sreekantaiah, 2007). Therefore, apt usage of FISH panels in aiding diagnosis or in monitoring follow-up samples of HMs is critical.

The present study was undertaken to compare the diagnostic yield between FISH and CCS in four different hematological malignancies. The hematological diseases considered in this project included Chronic Lymphoid Leukemia (CLL), Acute Lymphoid Leukemia (ALL), Multiple Myeloma (MM) and Myelodysplastic Syndrome. Our findings further inspect recurrence of commonly reported genetic abnormalities detected by FISH in a south Indian population.

Materials and Methods {#sec1-2}
=====================

Patients and sample preparation {#sec2-1}
-------------------------------

The current study included a total of 201 cases consisting of bone marrow and peripheral blood samples queried for several hematological malignancies between October 2014 and June 2017. The study consisted of 93 MDS cases, 42 ALL cases, 40 MM cases and 26 CLL cases. The samples were processed simultaneously for FISH panel and routine cytogenetic assessment. No plasma cell sorting was performed in MM cases. The samples were grouped into three categories based on karyotype and FISH analysis: Group 1 consisted of samples that showed concordant results by FISH and conventional cytogenetic investigation. Group 2 included samples where FISH proved advantageous over karyotype. This also included samples where metaphases were unavailable or insufficient. Finally, samples where karyotype delivered more information such as secondary abnormalities that was not targeted by FISH were classified in Group 3.

Conventional Cytogenetics {#sec2-2}
-------------------------

Heparinized, blood or whole bone marrow samples were cultured for 24 hours using RPMI-1640 media (Gibco Invitrogen, USA) containing 15% fetal bovine serum (Microphil, USA) and Pen-strep (Gibco Invitrogen, USA). Culture was terminated and processed with hypotonic solution (KCl 0.075 M) and fixed with Cornoy's Fixative (Methanol: Acetic Acid 3:1). Slides were prepared on grease free slides, checked for metaphases and aged overnight. Following day, G-banding using Trypsin and Geimsa staining was performed. The analysis was performed using Zesis Axio Imager Z2 microscope with Ikaros software (MetaSystems, GmBH, Germany). 20 metaphases were evaluated by two experienced cytogeneticists according to the International System for Human Cytogenomic Nomenclature (ISCN 2016). Clonality was established when more than three metaphases showed the same structural and/or numerical aberrations.

Fluorescent in Situ Hybridization {#sec2-3}
---------------------------------

All FISH assays were carried out in accordance to the manufacturers' specifications. Fixed cells were dropped onto microscopic slides and incubated at 55°C for up to 5 minutes. 10 µl of the probe mixture was applied to a 22 × 22 mm hybridization area. The marked area was sealed with rubber cement. The sample and probes were co-denatured at 75°C for 5 minutes and allowed to hybridize overnight at 37°C in a hybridization chamber (Statspin, ThermoBrite). Slides were washed in 0.4X SSC at 70°C for 2 minutes followed by 2X SSC/0.5% Tween 20 at room temperature for 30 seconds. Slides were then counterstained and mounted with 10 μl 4',6-diamidino-2-phenylindole (DAPI II, MetaSystems GmbH, Germany). FISH analyses were independently assessed by two cytogeneticists using Zesis Axio Imager fluorescent microscope with ISIS software (MetaSystems GmbH, Germany). A total of 200 interphase nuclei were scored per probe per slide by two experienced cytogeneticists. All probes were purchased either from MetaSystems, GmbH, Germany or CytoCell, UK. The specific details of probes for the FISH panels are summarized in [Table 1](#T1){ref-type="table"}.

###### 

List of Probes Included in the Present Study

  Disease                     Targeted genetic abnormality   FISH Panel Probes   Probe Color          Manufacturer name
  --------------------------- ------------------------------ ------------------- -------------------- -------------------
  Acute Lymphoid Leukemia     t(9;22)(q34;q11)               BCR/ABL1            Green/Red            MetaSystems
                              t(12;21)(p13;q22)              ETV6/RUNX1          Green/Red            MetaSystems
                              11q23 deletion                 MLL                 Yellow (Green+Red)   CytoCell
  Multiple Myeloma            -1/1p32 deletion               CDKN2C              Green                CytoCell
                              +1/1q21 amplification          CKS1B               Red                  CytoCell
                              -13/13q14 deletion             D13S319/13qter      Red/Green            CytoCell
                              14q32 rearrangement            IGH                 Yellow (Green+Red)   CytoCell
                              17p13/D17Z1 deletion           p53/CEP17           Red/Green            CytoCell
  Chronic Lymphoid Leukemia   -11q22/17p13 deletion          ATM/TP53            Green/Red            CytoCell
                              -13/13q14 deletion             D13S319/ LAMP1      Red/Blue             CytoCell
                              -12/12p11-q11                  CEP12               Green                CytoCell
                              -6/6q23 deletion               MYB/SEC63           Red/Green            CytoCell
  Myelodysplastic Syndrome    -5/5q31/5q32-33 deletion       EGR1/RPS14          Red/Green            CytoCell
                              -7/7q22/7q31 deletion          MLL5/MET            Red/Green            CytoCell
                              -20q12/20q13 deletion          PTPRT/MYBL2         Red/Green            CytoCell
                              +8/8p11-q11                    CEP8                Blue                 CytoCell

Results {#sec1-3}
=======

In a total of 201 cases of HM, 80 (39.8%) patients were positive for abnormalities by FISH and 36 (17.9%) showed abnormalities by routine cytogenetic analysis as represented in [Table 2](#T2){ref-type="table"}. The overall concordance between FISH and karyotype was found to be 58.7%. However, FISH could pick up chromosomal aberrations (CA) in 28.2% of the total cases that presented normal karyotype or culture failure. Inversely, karyotype detected chromosomal abnormalities in 12.9% of patients that were not targeted or negative by FISH investigation. Independent analysis of the diseases as shown in [Figure 1](#F1){ref-type="fig"} revealed that CLL patients benefited the most by FISH when compared to other HM's. MDS presented highest concordance (\>85%) between the two modalities indicating that FISH provided no additional information. Only in ALL, a significant population benefitted from karyotype investigation where 47.6% of patients showed an abnormal karyotype. Overall failure rate for CCS in HMs was 13.9% (28/201). Individual failure rates for CLL, ALL, MM and MDS were found to be 38.4%(10/26), 7.1%(3/42), 17.5%(7/40) and 8.6%(8/93), respectively. FISH provided a result in all 201 samples analyzed.

###### 

Abnormal Karyotype and Corresponding FISH Results of the Study Group for All the Hematological Malignancies.

  SN                             Karyotype                                                                                                                                               Fish Panel                                                                                     
  ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- ----------------- ----------------------------- ------------- ------
  1                              43,-X,-Y,+1,t(1;8)(p14;q24),-2,-4,add(7)(p21), t(13;14)(q10;q10), del(13)(q14;q32), add(16)(p13),+22 \[12\]/46,XY\[8\]                                  3G                               3-5R              1Y                            1G1R          2G2R
  2                              46-48,X,-X,+del(1)(q32),-3,add(4)(q33),-5, del(6) (q15), 10,+add(11)(q23), add(12)(p13)x2, ?del(13) (q32),-15, -17,+18, -20, +4 mar \[12\]/46,XX\[2\]   2G                               3R                1Y                            1R1G          1G1R
  3                              54,XY,del(1)(p13p32),del(1)(p13),+1,+3,+5,+7,+8,+9, +10,-13,+21, +21 \[16\]/46,XY\[4\]                                                                  2G                               3R                1Y1G1R                        1R1G          2G2R
  4                              57,X,-Y,+2,+3,+4,+5,+6,-8, +9,+11, +13,+14, +15, +17,+19,20,+21,+22\[5\] /46,XY\[15\]                                                                   2G                               3R                2Y                            2G2R          3G3R
  Chronic Lymphocytic Leukemia   6q23 (MYB/SEC63)                                                                                                                                        CEP 12                           13q14 (D13S319)   11q22 (ATM)                   17p13 (p53)   
  5                              47,XX,+12\[5\]/46,XX\[25\]                                                                                                                              2R2G                             3G                2R2B                          2R            2G
  Acute Lymphocytic Leukemia     t(9;22)(q34;q11) (BCR/ABL1)                                                                                                                             t(12;21)(p13;q22) (ETV6/RUNX1)   11q23 (MLL)                                                   
  6                              46,XX, t(9;22))(q34;q11) \[10\]/46,XX\[5\]                                                                                                              1G1R2Y                           2G2R              1Y                                          
  7                              46,XY,t(3;12;21)(p13;p13;q22),del(6)(q21),add(12)(p13),del(17)(q22) \[12\] /46,XY\[8\]                                                                  2G2R                             2G2R1Y            1Y                                          
  8                              46,XY,t(9;22)(q34;q11)\[7\]/46,XY,t(2;3)(q31;q27),t(9;22)(q34;q11)\[3\]                                                                                 1G1R2Y                           2G2R              2Y                                          
  9                              46,XX\[13\]/58,XX,+4,+5,+6,+8,+9,+10, +11,+12,+14, +15,+21,+21\[2\]                                                                                     2G2R                             2R4G              2Y                                          
  10                             46,XY ,?add(9)(p), t(9;22)(q34;q11)\[15\]                                                                                                               1G1R2Y                           2G2R              2Y                                          
  11                             52,XY,+X,+6,+14,+17,+21,+21\[20\]                                                                                                                       1G1R2Y                           2R3G/2R4G         2Y                                          
  12                             46,XX,del(2)(q11),t(10;11)(p13;q23),der(14)t(1;14)(q21;p11)\[16\]/ 46,XX\[4\]                                                                           1G1R2Y                           1G1R2Y            1Y1G1R                                      
  13                             47,XX,add(7)(p11),-11,der(12)t(12;?)(p11;?), -20,+21, -22,+3-4 mar \[9\]/ 46,XX\[16\]                                                                   1G1R2Y                           1R3G              2Y                                          
  14                             60,XY,+X,dirdup(1)(q21-qter) ,+4,+6, +7, +9, +14, +15,+17, +20, +21, +3 mar\[15\]                                                                       2G2R                             2R4G              2Y                                          
  15                             45,XY,t(9;22)(q34;q11),-18, der(20)t(18;20) (q11;q13) \[20\]                                                                                            2G1R1F                           2G2R              2Y                                          
  16                             51-60,XX,-Y,add(2 p21),+add(3p21)x2,+del (4q24), +8,+21,+21\[15\]                                                                                       2G2R                             2R3G/2R4G         2Y                                          
  17                             54,XY,+X,+4,+5,+i(7)(q10),+8,+10,+14, +21\[18\]                                                                                                         2G2R                             2R3G              2Y                                          
  18                             46,del(1q31),?dup(2q21q31),del(9p13),del(14q) \[19\]/46,XY\[1\]                                                                                         2G2R                             2G2R              2Y                                          
  19                             44-46,X,-Y,-5,add(7)(p12),add(12),(p11),+1,-2 mar\[13\] /46,XY\[7\]                                                                                     2G2R                             2G1R              2Y                                          
  20                             46-48,XY,+1,-2mar\[12\]                                                                                                                                 2G2R                             2R1Y              2Y                                          
  21                             46,XY,t(2;5)(q21;p15)\[20\]                                                                                                                             2G2R                             2G2R              2Y                                          
  22                             46,XY,t(9;15)(q34;q11),?del(13)(q14)\[12\]/46,XY\[8\]                                                                                                   2G2R                             2G2R              2Y                                          
  23                             46, XY t(2;7)(p14;p22) \[15\] / 46,XY\[5\]                                                                                                              2G2R                             2G2R              2Y                                          
  24                             46,XY,i(7)(q10), del(9)(p13)\[7\]/46,XY\[1\]                                                                                                            2G2R                             2G2R              2Y                                          
  25                             46,i(X)(q10),Y\[20\]                                                                                                                                    2G2R                             2G2R              2Y                                          
  Myelodysplastic Syndrome       -5q31/-5q32-33 (EGR1/RPS14)                                                                                                                             -7q22/-7q31 (MLL5/MET)           CEP 8             -20q12/-20q13 (PTPRT/ MYBL2                 
  26                             45,XX,-7\[1\]                                                                                                                                           2G2R                             1R1G              2B                            2G2R          
  27                             45,XX,-7\[30\]                                                                                                                                          2G2R                             1G1R              2B                            2G2R          
  28                             45,XX,-7,del(20)(q12)\[15\]                                                                                                                             2G2R                             1G1R              2B                            1G1R          
  29                             46,XX,del(5)(q21)\[10\]                                                                                                                                 1G2R                             2G2R              2B                            2G2R          
  30                             60,XY,+X,add(1)(p35),+5,+5,+5,+del(6)(q23),+7,+10, +12,+14,+15,+17,+18,+21,+22/46,XY,del(6)(q23) \[3\]/46,XY\[20\]                                      3G3R                             3G3R              2B                            2G2R          
  31                             47,XX,+8\[1\]                                                                                                                                           2G1R                             2G2R              3B                            2G2R          
  32                             45,XY,t(3;11)(p?;q32),-5\[8\]                                                                                                                           1G1R                             2G2R              2B                            2G2R          
  33                             47,XX,dup(5)(q13;q31),+8,del(14)(q23;q32)\[10\]                                                                                                         2G1R                             2R2G              3B                            2G2R          
  34                             47,XY,del(3)(q22),-5,?del (7)(q32q33),+8,+15, ?del(20)(q13)\[6\]                                                                                        2G1R                             1R1G              3B                            1R1G          
  35                             46,XY,trp(1)(q21;q32),add(3)(q26),add(19)(p13)\[15\]                                                                                                    2G2R                             2G2R              2B                            2G2R          
  36                             46,XY,t(6;9)(p22;q34)\[20\]                                                                                                                             2G2R                             2G2R              2B                            2G2R          

![Graph Showing Percentage of Group 1 (concordance between the two modalities), Group 2 (FISH advantageous) and Group 3 (CCS advantageous). X-axis: Sample size (%), Y-axis: Individual HMs.](APJCP-18-3457-g001){#F1}

CLL {#sec2-4}
---

Of the 26 samples received for CCS and FISH analysis, only one case (3.8%) was diagnosed positive by karyotype, contrastingly 17 cases (65.4%) were diagnosed positive by FISH. In 16 cases (61.5%) FISH identified an abnormality not detected by CCS, which either yielded a normal karyotype or culture failure. Using our CLL FISH panel on fixed samples, abnormalities were analyzed for each of the probes, with the highest rate observed in deletion of 13q14 (D13S319). As illustrated in [Figure 2](#F2){ref-type="fig"}, 47.1% of the positive cases (8/17) showed loss of the 13q14 (D13S319) segment in a range of 25-80% of interphase nuclei, 41.1% (7/17) depicted trisomy 12 in 45-95% of nuclei and 11.7% (2/17) showed deletions of 17p13 (p53) in 30-65% of cells and 11q22 (ATM) in 20-70% of cells. In only one case, CCS picked up trisomy 12 in 20% of the metaphases analyzed. FISH investigation established higher population of the clone where the aberration was picked up in greater than 60% of interphase nuclei. No abnormality was detected for probe locus 6q23 (MYB).

![Graphical Representation of CA Picked up by FISH in HM, X-axis: Chromosomal Aberration targeted by specific FISH probe, Y-axis: Incidence in percentage within FISH positive sample group](APJCP-18-3457-g002){#F2}

MM {#sec2-5}
--

Analysis of 40 whole bone marrow samples revealed only 4 cases (10.0%) were diagnosed positive by karyotype. On the contrary, 21 cases (52.5%) were diagnosed positive by FISH. In 42.5% of cases, FISH proved advantageous in identifying an abnormality not detected by CCS that exhibited a normal karyotype or culture failure. Using our MM FISH panel, abnormalities were tested for each of the probes, with the most frequent CA being amplification of 1q21 (CKS1B). As illustrated in [Figure 2](#F2){ref-type="fig"}, 61.9% of positive cases (13/21) showed amplification of the 1q21 (CKS1B) segment in a range of 15-55% of interphase nuclei, 11.7% (2/21) displayed deletion of 1p32 (CDKN2C) in 15-55% of nuclei, 47.1% (8/21) had deletion of 13q14 (D13S319) in 15-75% of nuclei, 29.4% (5/21) presented rearrangement of 14q32 (IgH) in 20-55% of cells and 17.6% (3/21) had deletion of 17p13 (p53) in 25-40% of interphase nuclei. CCS could pick up structural and numerical abnormalities in addition to FISH findings in only 10% (4/40) of the total cases. The abnormalities included t(1;8)(p13;q24), add(4)(q?), del(6)(q?), add(7)(p21) and copy number changes of other chromosomes not targeted by FISH.

MDS {#sec2-6}
---

Of the 93 samples received for cytogenetic and FISH analysis, 11 cases (11.8%) were diagnosed positive by karyotype. In addition, 16 cases (17.2%) were diagnosed positive by FISH. FISH was observed to be least advantageous in providing additional information compared to other HM's where CA was detected in less than 15% of cases exhibiting normal karyotype or culture failure. FISH and karyotype showed 90.9% positive concordance and 94.6% negative concordance. Using our MDS FISH panel, abnormalities were verified for each of the probes, and deletion of 5q31 (EGR1/RPS14) was observed to be most predominant. As illustrated in [Figure 2](#F2){ref-type="fig"}, 50% (8/16) of positive cases showed deletion of 5q31 (EGR1/RPS14) segment in a range of 30 - 70% of interphase nuclei, 37.5% (6/16) carried deletion of 7q22 (MLL5/MET) in 20-50% of interphase nuclei and deletion of 20q12 (PTPRT/MYBL2) in 20-60% of nuclei, and 31.2% (5/16) presented trisomy 8 in 15-60% of nuclei. CCS could pick up structural and numerical abnormalities in addition to FISH findings in only 4.3% (4/93) of the total cases. The abnormalities included t(3;11)(p?;q32), dup(1)(q21q32), add(3)(q26), add(19)(p13) and copy number changes of chromosomes not targeted by FISH.

ALL {#sec2-7}
---

Of the 42 samples received for cytogenetic and FISH analysis 80.9% (34/42) were pediatric cases. 20 of total cases (47.6%) were diagnosed positive by karyotype. In contrast, 26 of total cases (61.9%) were diagnosed positive by FISH, 23 of which were pediatric. In 15 cases (35.7%), FISH identified an abnormality not detected by CCS yielding a normal karyotype or culture failure. Copy number changes of RUNX1 was observed in 38.4% (10/26) of total cases and 39.1% (9/23) in pediatric cases which was the most common CA in this study. As illustrated in [Figure 2](#F2){ref-type="fig"}, 7.6% (2/26) of the positive cases showed t(12;21)(p13;q22) (ETV6/RUNX1) translocation and 15.3% (5/26) showed deletion of ETV6 gene in a range of 10-95% of interphase nuclei, 19.2% (5/26) presented t(9;22)(q34;q11) (BCR/ABL) translocation in 50-80% of nuclei and 15.4% (4/26) showed rearrangement of 11q23 (MLL) in 40-95% of nuclei analyzed. CCS could pick up additional numerical abnormalities which were not identified by FISH in 33.3% (14/42) such as +4, +5, +6, +8, +10, +14, +15, +17, +20 and structural aberrations such as t(2;5)(q21;p15), t(9;15)(q34;q11), del(13)(q14), t(2;7)(p14;p22), i(7)(q10), del(9p13), del(6)(q21), del(17)(q22), 46,XY,t(2;3)(q31;q27), del(2)(q11), der(14)t(1;14)(q21;p11), add(7)(p11), dirdup(1)(q21-qter), der(20)t(18;20)(q11;q13), dup(2q21q31).

Discussion {#sec1-4}
==========

In this comparative study, the diagnostic utility of FISH in comparison to CCS was found to be most advantageous in CLL and least advantageous in MDS. The percentages of additional genetic aberrations identified by FISH alone were 65.3% for CLL, 45% for MM, 31% for ALL and 14% for MDS.

According to our study, it is evident that FISH did not add relevant information with respect to chromosomal aberrations in comparison to CCS in MDS. In agreement with our results, CA detection rate of lesser than 15% by FISH has been reported in several studies (Ketterling et al., 2002; Cherry et al., 2003; Costa et al., 2010; Pitchford et al., 2010; Yang et al., 2010). In the current study, MDS had the highest concordance value of more than 90% between the two modalities. FISH testing in MDS could have an advantage when CCS fails or yields chromosomes of poor morphology. A study by Yang et al. (2010) concluded that FISH testing maybe informative in high grade MDS where CCS yields a normal karyotype. We report deletions of 5q31/-5, 7q22/-7, Trisomy 8 and -20q12/-20 in 50%, 37.5%, 31.2% and 37.5% respectively of all abnormal cases of MDS by FISH. Combined positive pick up by CCS and FISH was less than 20% in the current study. This can be attributed to the case selection which included a heterogeneous population of patients at primary diagnosis and post therapy monitoring. CA in CLL are important independent predictors of disease progression and survival and improving the detection rate of these aberrations can help develop a better design for treatment strategies (Wiktor and Van Dyke, 2004). Many recent studies have demonstrated the benefits of using a single mitogen or in combination to augment diagnostic yield by CCS and FISH in detection of CA (Shi et al., 2013; Dubuc et al., 2016; Holmes et al., 2016). Contradictory to the findings in MDS, our study showed that FISH was found to be an invaluable tool for picking up CA in lymphoid malignancies. FISH identified CA where CCS was normal or insufficient in 61.5% (16/26) of CLL, 35.7% (15/42) of ALL and 42.5% (17/40) of MM. In CLL, while a low mitotic index may preclude complete cytogenetic analysis, FISH testing reveals aberrations in non-dividing cells and the identification of a minor cell population or an emerging clone. A Chinese study conducted by Qin et al., (2016) demonstrated that CLL FISH showed higher sensitivity in unveiling chromosomal abnormalities than by CCS. 73.8% of cases demonstrated a CA detected by FISH in comparison to 9.5% by CCS. This corroborates our findings where 65.4% of positive cases were diagnosed by FISH and only 3.8% (1/26) of cases by CCS. CLL exhibited the least concordance between the two modalities. Deletion of 13q14/-13 (D13S319/LAMP1), Trisomy 12, deletion of 11q22 (ATM) and deletion of 17p13 (p53) were found in 47.1%, 41.1%, 11.7% and 11.7% respectively of all CLL positive cases. As represented in [Figure 3](#F3){ref-type="fig"}, hemizygous deletion and monosomic FISH patterns were observed for 13q14. Previous Indian and other Asian studies have also reported deletion of 13q14 as the most prevalent CA identified by FISH (Xu et al., 2008; Amare et al., 2013; Wu et al., 2013; Yi et al., 2017). None of the cases exhibited deletion of 6q23 in our study making it the least prevalent in our population. Similar conclusions have been drawn in other Asian studies (Xu et al., 2008; Amare et al., 2013).

![Signal Pattern for Select FISH Probes Included; A: BCR/ABL double fusion (1G1R2Y), B: 3 copies of ABL (3R), C: Single fusion of BCR/ABL with ABL deletion (2G1R1Y), D: Atypical ETV6/RUNX1 fusion indicating 3-way translocation (1Y2G2R), E: RUNX1 amplification (2R4G), F. ETV6 deletion (1R2G), G. Hemizygous deletion of D13S319(2B1R), H. Monosomy 13 (1R1B), I. Trisomy 12 (3G), J. CKS1B amplification (5R), K. IGH break apart (1Y1R1G), L. Trisomy 8 (3B)](APJCP-18-3457-g003){#F3}

We observed that FISH testing also benefitted multiple myeloma significantly. Contrasting to other HMs in which the malignant clone tends to dominate the bone marrow at diagnosis, MM is hindered by low detection of CA because of hypoproliferative nature of plasma cells and normal metaphases that originate from the myeloid cells in the marrow. This limitation in MM diagnostics is countered by implementing plasma cell enrichment by sorting or immunofluorescence assays such as cIg-FISH (Cytoplasmic Immuno Globin) (Shetty et al., 2012; Gole et al., 2014). Although in our present study, CCS and FISH were performed on whole bone marrow samples, CA was identified in 52.5% (21/40) of cases by FISH and 10.0% (4/40) by CCS. In a study, Amare et al (2016) reported a positive pick up rate of 66% by FISH on plasma cell sorted samples. MM exhibited 50% concordance between CC and FISH, with FISH adding value in 45% (18/40) of the cases. Amplification of 1q21, deletion of 1p32, deletion of 13q14, rearrangement of 14q32 and deletion of 17p13 were present in 61.9%, 11.7%, 47.1%, 29.4%, 17.6% of abnormal cases respectively. We observed 1q21 amplification to be the most common CA diagnosed by FISH confirming similar studies (Kwon et al., 2010; Amare et al., 2016). Amplification of 1q21 has been reported to be more prevalent than deletion of 1p32 and has been positively correlated with IGH rearrangement and 13q/13 deletion (Lim et al., 2013). This was evident in our study where amplification of 1q21 was seven times more frequent than deletion of 1p32 (13:2 cases, 1p21:1q32) concurrent with IGH rearrangement in 30.7% and -13q/-13 in 38.4% of 1q21 positive cases. As reported by many studies, -13/-13q14 is present in about 40% to 50% of cases and thus is one of the most frequent abnormalities in MM (Liebisch and Dohner, 2006; Zang et al., 2015). But our study revealed -13/-13q14 to be the second most common CA with a percentage of 47. Among all prognostic markers, deletion of TP53/monosomy 17 is considered worst prognosis and a late event in the evolution of MM (Cremer et al., 2005). Our study reports only 3 patients with TP53 deletion of which two patients also presented with 1q21 amplification and one patient presented with 13q14 deletion.

In ALL, non-random chromosomal abnormalities have important biological, diagnostic, and prognostic significance. In this study, CA was identified in 61.9% (26/42) of cases by FISH and 47.6% (20/42) by CCS with a concordance of 40.3% between the modalities. CCS was advantageous in 33.3% (14/42) of the ALL cases which is the highest across all the HMs included in this study. CCS was able to pick up numerical aberrations such as aneusomies of +4, +5, +6, +8, +10, +14, +15, +17, +20 and structural aberrations such as t(2;5)(q21;p15), t(9;15)(q34;q11), del(13)(q14), t(2;7)(p14;p22), i(7)q, del(9p13), del(6)(q21), del(17)(q22), 46,XY,t(2;3)(q31;q27), del(2)(q11), der(14)t(1;14)(q21;p11), add(7)(p11), dirdup(1)(q21-qter), der(20)t(18;20)(q11;q13), dup(2q21q31). Increased copy number changes of RUNX-1 was the most common aberration diagnosed by FISH representing 38% of the cases considered. Similar findings have reported increased copy numbers of RUNX-1 as the most frequent CA diagnosed by FISH (Udaykumar et al., 2007; Haltrichl et al., 2008). t(12;21), t(9;22) and 11q23 MLL break apart was found in 7.6%, 19.2% and 15.4% of samples respectively. Deletion of 12p13 (ETV6) was found in 15.4% of the total FISH positive cases and copy number changes in other chromosomes (trisomy 9, 11, 22) targeted by FISH was found in 15.4%. These results were similar to that reported by Mazloumi et al (2012) where the most common translocation was t(9;22)(q34;q11) in 12.7% of patients. As represented in [Figure 3](#F3){ref-type="fig"}, varied FISH patterns were observed for BCR/ABL1 representing dual fusion, single fusion and trisomy of chromosome 9. Consistent with our results, previous studies also conclude that CCS is still a relevant and important test in the diagnostics of ALL (Freidman and Weinstein et al., 2000; Harrison, 2001; Soszynska et al., 2008).

As summarised in [Figure 1](#F1){ref-type="fig"}, it is evident that each haematological malignancy presents chromosomal aberrations which can be detected effectively either by CCS or FISH or in tandem. Although, interphase FISH was found to be a reliable and targeted technique for detecting cryptic abnormalities in whole bone marrow samples of HMs, we observed that CCS is sufficient or adds value in diagnostics of certain haematological malignancies. Presenting a high concordance value greater than 90% in MDS, FISH testing is limited to specific scenarios where CCS fails to furnish a conclusive report or presents with a normal karyotype with low mitotic index. On the contrary, the characteristic complexity of genetics in ALL benefitted most by CCS testing which detected additional abnormalities not focussed in FISH panel, thus recommending combined application of these modalities.

A widespread combination of cytogenetic markers specific to disease profile is necessary to augment risk stratification and monitoring of hematological malignancies. Karyotyping continues to remain the gold standard in cytogenetic investigation of hematological malignancies owing to its comprehensive purview of the genome and requirement of relatively simple infrastructure. However, by overcoming the limitations of karyotyping, FISH has proven to become an important tool in routine diagnosis. Therefore, a cost-effective approach for genetic studies by I-FISH and G-banding should be considered such that maximum information about the disease may be achieved.
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